An Advanced Biosensor for Molecular Interaction Studies.
用于分子相互作用研究的先进生物传感器。
基本信息
- 批准号:8516144
- 负责人:
- 金额:$ 60.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionAffinityAlgorithmsBackBaclofenBenchmarkingBenignBindingBiologicalBiological AssayBiological MarkersBiological ProcessBiological SciencesBiologyBiosensorBuffersCXCR4 geneCalibrationCalorimetryCarbonic Anhydrase IICatalysisCell WallCell physiologyCellsChemicalsChemistryCommercial SectorsCommunitiesComplexComputersDataData CollectionDetectionDetergentsDevicesDiagnosticDiagnostic ProcedureDimethyl SulfoxideEdetic AcidElectronicsEnvironmentEventExcisionExperimental ModelsFeedbackFlowersFluorescenceFoundationsG Protein-Coupled Receptor GenesGlassGlycerolGrantHIV ProteaseHydrogen BondingImmobilizationInjection of therapeutic agentInterferometryKineticsLabelLaboratoriesLasersLeadLifeLightLiquid substanceLiteratureMalignant NeoplasmsMeasurementMeasuresMedicalMembraneMembrane ProteinsMethodologyMethodsMicrofluidicsMolecularMonitorNoiseOpticsOrganic solvent productPTGS2 genePatternPerformancePharmaceutical PreparationsPharmacologic SubstancePhasePhysiologicalPlasticsPositioning AttributeProcessProtocols documentationRadioactiveReactionRefractive IndicesReproducibilityResearchResearch PersonnelRunningSamplingSampling StudiesSchemeScienceSerumSignal TransductionSilicon DioxideSiteSmall Business Technology Transfer ResearchSolutionsSpeedStromal Cell-Derived Factor 1SucroseSulfanilamideSurfaceSystemTechniquesTechnologyTechnology TransferTestingThermodynamicsTimeTitrationsTrainingTranslationsTreatment EfficacyValidationVesicleWaterbasecatalystcommercializationcostdesigndrug discoveryevaluation/testinggamma-Aminobutyric Acidgraphical user interfaceimprovedinnovationinstrumentinterestmeetingsmultidisciplinaryoperationprototypepublic health relevanceresearch and developmentsensorsmall moleculetooluser-friendly
项目摘要
DESCRIPTION (provided by applicant): Molecular interactions form the foundation of biology and chemistry. They are central to life itself and determine catalytic activity, cellular function,
and therapeutic efficacy. The vast majority of diagnostic procedures depend on some type of specific molecular interaction. Therefore, the ability to perform pure liquid-phase molecular binding analysis at high sensitivity, without modifying the interacting species, and at physiological concentrations would be revolutionary. Yet, the tools available to quantify these interactions have limitations. Traditional methods such as the sucrose gradient technique or isothermal titrimetric calorimetry are laborious and require substantial quantities of sample to perform an assay. Fluorescence and radioactive methods are sensitive, but rely on the incorporation of signaling labels to enable detection, slowing the assay and increasing its cost. Numerous techniques, particularly the label-free methods, require surface immobilization of one of the interacting moieties putting the species in a non-native environment. Labels and tethers can be benign, but often alter the interacting molecules and can lead to a biased result. Recently my group and others demonstrated that back-scattering interferometry (BSI) can be used in the academic laboratory to perform molecular interaction determinations label-free and in free-solution, with sensitivity that allows assays on small quantities of sample, at physiologically relevant concentrations. BSI is a universal sensing method that only requires the product of a reaction to refract or interact with light differently than the participating species,
therefore has the potential to be widely applicable for general use as a Molecular Interaction Photometer (MIP). BSI is a prime candidate to become an MIP because it has a simple and inexpensive optical train comprised of a He-Ne laser, a microfluidic channel, and a position sensor allowing minute refractive index changes to be monitored. Measurements are made within a microfluidic channel formed in glass, fused silica, or plastic and at physiologically relevant concentrations in complex matrices such as serum or with native membrane- proteins. Yet the current academic embodiment of BSI is not commercially viable. Tedious alignment methods, immature transduction schemes, poorly refined sample handling and introduction methods, and performance limitations due to environmental noise sensitivity all impede the wide dissemination and adoption of BSI in the life science and drug discovery communities. Under Phase I of this STTR grant we met our milestones demonstrating a two-channel BSI instrument with a pipette-driven injection method and a fringe detection algorithm that simplified fringe selection and alignment. Here we propose to build on these results, while capitalizing on two new innovations to transform our academic laboratory BSI into the MIP instrument we call NanoBIND. Under this STTR Phase II, we propose the completion of four aims to refine BSI through research development and technology transfer, facilitate commercialization by Molecular Sensing Inc. and allow the subsequent broad dissemination in the research community. In Aim 1 we further simplify the optical train, while retaining the advantages of performing a simultaneous sample-reference determination. Aim 2 implements a sample introduction method that is user friendly, minimizes the potential for contamination and constrains volumes to <1?L. An improved algorithm enhances sensitivity, enables electronic fringe selection and alignment and addresses non-specific interactions (at cell wall) to improve assay reproducibility in Aim 3. And in Aim 4 ?- prototype version BSI systems will be constructed and used, external to Vanderbilt and MSI, to demonstrate that BSI gives meaningful and quantitative binding affinity values (from ?M to pM) and that it can be used to screen for molecular interactions in complex matrices such as serum and cell-free media, as well as DMSO. Upon completion of these Aims, three identical prototypes will have been constructed and evaluated for field utility. Feedback from these laboratories and users will provide the formal
framework for refining the design under Phase III commercial deployment.
描述(申请者提供):分子相互作用是生物学和化学的基础。它们是生命本身的核心,决定着催化活性、细胞功能、
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DARRYL J. BORNHOP其他文献
DARRYL J. BORNHOP的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DARRYL J. BORNHOP', 18)}}的其他基金
Translation of Interferometric-based Free-solution Assay Methodology
基于干涉测量的自由溶液测定方法的转化
- 批准号:
10254477 - 财政年份:2021
- 资助金额:
$ 60.46万 - 项目类别:
An Advanced Biosensor for Molecular Interaction Studies
用于分子相互作用研究的先进生物传感器
- 批准号:
7999170 - 财政年份:2010
- 资助金额:
$ 60.46万 - 项目类别:
An Advanced Biosensor for Molecular Interaction Studies.
用于分子相互作用研究的先进生物传感器。
- 批准号:
8683192 - 财政年份:2010
- 资助金额:
$ 60.46万 - 项目类别:
Interferometric Nano-sensing for Biochemical Analysis
用于生化分析的干涉纳米传感
- 批准号:
7226192 - 财政年份:2005
- 资助金额:
$ 60.46万 - 项目类别:
Interferometric Nano-sensing for Biochemical Analysis
用于生化分析的干涉纳米传感
- 批准号:
6970011 - 财政年份:2005
- 资助金额:
$ 60.46万 - 项目类别:
Interferometric Nano-sensing for Biochemical Analysis
用于生化分析的干涉纳米传感
- 批准号:
7086118 - 财政年份:2005
- 资助金额:
$ 60.46万 - 项目类别:
Interferometric Nano-sensing for Biochemical Analysis
用于生化分析的干涉纳米传感
- 批准号:
7407503 - 财政年份:2005
- 资助金额:
$ 60.46万 - 项目类别:
PICOLITER LASER-BASED ABSORBANCE AND RI DETECTOR
皮升激光吸光度和 RI 检测器
- 批准号:
3498108 - 财政年份:1988
- 资助金额:
$ 60.46万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 60.46万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 60.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 60.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 60.46万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 60.46万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 60.46万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 60.46万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 60.46万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 60.46万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 60.46万 - 项目类别:
Standard Grant














{{item.name}}会员




